The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma (Q27853223)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma	scientific article

Statements

scholarly article

1 reference

13 November 2016

The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma (English)

1 reference

13 November 2016

0 references

immunohistochemistry

1 reference

based on heuristic

inferred from title

esophageal squamous cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

J Jia

1

0 references

Y Cui

2

0 references

M Lu

3

0 references

X Wang

4

0 references

Jie Li

5

0 references

Jian Li

6

0 references

Y Li

7

0 references

X Zhang

8

0 references

J Gao

9

0 references

J Zhou

10

0 references

Z Lu

11

0 references

J Gong

12

0 references

J Yu

13

0 references

Z Sun

14

0 references

C Liu

15

0 references

L Shen

16

0 references

publication date

June 2016

0 references

Clinical and Translational Oncology

0 references

18

0 references

6

0 references

592-8

0 references

describes a project that uses

immunohistochemistry

1 reference

based on heuristic

inferred from title

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1406-8

21 January 2018

Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26459251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26459251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence, survival and prevalence of esophageal and gastric cancer in Linzhou city from 2003 to 2009.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26459251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26459251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/26459251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-015-1406-8

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

release_knutavijqvhwpf74siwcxucwoi

1 reference

https://api.fatcat.wiki/v0/release/knutavijqvhwpf74siwcxucwoi

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

13 November 2016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853223&oldid=2177418466"